July 2009 Volume 6 Number 7
Visit Nature Reviews Gastroenterology & Hepatology online to browse the
journal.
Now available at
http://links.ealert.nature.com/ctt?kn=38&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Gastroenterology & Hepatology online. To purchase a
subscription, please visit:
http://links.ealert.nature.com/ctt?kn=44&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=61&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
*********************************************************************
Nature Reviews Gastroenterology & Hepatology Impact Factor: 4.415*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
UCSD Clinical and Translational Research Institute and Nature Medicine
present:
Frontiers of Clinical Investigation Symposium
Metabolism 2009: From Bench to Bedside
October 8-10, 2009
La Jolla, California, USA
The theme for this year's symposium explores innovative approaches to
bridge laboratory investigation to clinical research in metabolism.
Early Bird Deadline: September 8, 2009
Abstract Submission: Deadline: August 21, 2009
For more information visit:
http://links.ealert.nature.com/ctt?kn=56&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
The burdens of digestive diseases
Stephen B. Hanauer
p377 | doi:10.1038/nrgastro.2009.104
http://links.ealert.nature.com/ctt?kn=32&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Liver: Simvastatin might be an effective therapy for portal hypertension
in cirrhosis
p379 | doi:10.1038/nrgastro.2009.96
http://links.ealert.nature.com/ctt?kn=43&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Hepatitis C: Angiotensin blockade-halting liver fibrosis
p380 | doi:10.1038/nrgastro.2009.91
http://links.ealert.nature.com/ctt?kn=7&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Cirrhosis: PPI use is associated with bacterial peritonitis
p380 | doi:10.1038/nrgastro.2009.98
http://links.ealert.nature.com/ctt?kn=67&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Targeted therapy proves promising
p381 | doi:10.1038/nrgastro.2009.76
http://links.ealert.nature.com/ctt?kn=81&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Celiac disease: Increased celiac disease in IBS
p381 | doi:10.1038/nrgastro.2009.93
http://links.ealert.nature.com/ctt?kn=71&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Surgery: Acute appendicitis-antibiotics versus appendicectomy
p381 | doi:10.1038/nrgastro.2009.95
http://links.ealert.nature.com/ctt?kn=36&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Large intestine: Exercise decreases risk of diverticular complications
p382 | doi:10.1038/nrgastro.2009.94
http://links.ealert.nature.com/ctt?kn=50&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Pancreas: EUS-guided celiac plexus block for pain management
p382 | doi:10.1038/nrgastro.2009.97
http://links.ealert.nature.com/ctt?kn=21&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Hepatitis: HCV variability, the immune system and resistance to antiviral
drugs
Jean-Michel Pawlotsky
p383 | doi:10.1038/nrgastro.2009.102
Several novel antiviral treatments for HCV are in preclinical or clinical
development, and most target viral enzymes and their functions. These new
drugs all potentially select for resistant viral variants, both in vitro
and in vivo; viral resistance is, therefore, likely to become an important
issue in clinical practice.
http://links.ealert.nature.com/ctt?kn=65&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Stomach: Quadruple therapy for Helicobacter pylori eradication
Javier P. Gisbert
p385 | doi:10.1038/nrgastro.2009.101
The low success rates of standard triple-therapy regimens for eradication
of Helicobacter pylori infection have led to development of alternative
approaches. Findings from a new meta-analysis that compared the efficacy
of concomitant quadruple therapy with that of standard triple therapy
revealed the concomitant approach to be superior for eradication of H. pylori.
http://links.ealert.nature.com/ctt?kn=68&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Ulcerative colitis: Natural history-an optimistic message from Norway
Laurent Peyrin-Biroulet and Jean-Frederic Colombel
p387 | doi:10.1038/nrgastro.2009.100
Selection of an optimum treatment regimen for patients with ulcerative
colitis depends on several factors, including the natural history of the
disease. A new study indicates that prognosis for patients with newly
diagnosed ulcerative colitis might not be as bad as typically thought-an
important finding that should be taken into account when the risks and
benefits of future treatment strategies are discussed.
http://links.ealert.nature.com/ctt?kn=34&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Surgery: New indications for laparoscopic sigmoidectomy
Badma Bashankaev and Steven D. Wexner
p388 | doi:10.1038/nrgastro.2009.99
Current recommendations for the performance of laparoscopic sigmoidectomy
in patients with diverticulitis reserve this procedure for individuals
who have complications of the disease or have had numerous, severe disease
episodes. Findings from a 2009 study challenge this dogma and suggest that
patients' quality of life should also be considered.
http://links.ealert.nature.com/ctt?kn=87&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Surgery: Laparoscopy for suspected appendicitis
Roland E. Andersson
p390 | doi:10.1038/nrgastro.2009.85
The routine use of diagnostic laparoscopy for young women who present with
right iliac fossa pain reduces the rate of negative appendectomy, according
to a new study. However, the implementation of laparoscopy as a routine
approach for the diagnosis of suspected acute appendicitis would probably
increase morbidity and mortality for these patients.
http://links.ealert.nature.com/ctt?kn=1&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Mucosal ablation of Barrett esophagus
Irving Waxman and Vani J. A. Konda
Published online: 02 June 2009
p393 | doi:10.1038/nrgastro.2009.90
Patients with Barrett esophagus and high-grade dysplasia or intramucosal
carcinoma have traditionally been managed by esophagectomy. However, the
development of endoscopic ablative therapies has changed this management
approach. This Review discusses the different endoscopic ablative therapies
currently available including tissue-acquiring and non-tissue-acquiring
modalities. The success rates and complications of the different techniques
are also addressed.
Abstract: http://links.ealert.nature.com/ctt?kn=85&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=29&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
New and experimental therapies for HCV
Arema A. Pereira and Ira M. Jacobson
p403 | doi:10.1038/nrgastro.2009.92
Standard treatment with pegylated interferon and ribavirin only cures just
over half of patients with HCV infection. Pereira and Jacobson review the
evidence on the efficacy and promise of several specifically targeted
antiviral therapies, which, most likely in combination with interferon
and ribavirin, may improve the success rate of HCV therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=33&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=83&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Pancreatic cancer: molecular pathogenesis and new therapeutic targets
Han H. Wong and Nicholas R. Lemoine
Published online: 09 June 2009
p412 | doi:10.1038/nrgastro.2009.89
Pancreatic cancer is lethal and notoriously difficult to treat, therefore,
there is an urgent need to develop new therapeutic and diagnostic
modalities. This Review discusses the agents that have been developed to
target the pathways and processes involved in pancreatic tumorigenesis,
and reviews the results of laboratory and clinical trials of these agents.
Future therapeutic targets are also discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=42&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=86&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Targeted therapy for hepatocellular carcinoma
Hans Christian Spangenberg, Robert Thimme and Hubert E. Blum
Published online: 02 June 2009
p423 | doi:10.1038/nrgastro.2009.86
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors
worldwide. Treatment options for patients with advanced HCC are limited
because of the lack of effective chemotherapeutic agents. This Review
discusses the mechanisms of targeted therapies and describes clinical
studies that have investigated the safety and efficacy of these therapies
in patients with HCC. Perspectives for future developments are also provided.
Abstract: http://links.ealert.nature.com/ctt?kn=72&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=62&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease
Florian Beigel, Matthias J�rgens, Cornelia Tillack, Marion Subklewe,
Doris Mayr, Burkhard Goke, Stephan Brand and Thomas Ochsenkuhn
p433 | doi:10.1038/nrgastro.2009.87
This article considers the case of a 58-year-old man who presented with
a 35-year history of Crohn's disease, pararectal fistulas and abscess
formation. He had been taking azathioprine therapy for approximately
5.5 years. He was started on infliximab; however, his fistulas persisted
and the abscess recurred. He was, therefore, switched to adalimumab. After
development of pancytopenia, a bone marrow biopsy and a diagnostic
splenectomy were performed, leading to a diagnosis of hepatosplenic T-cell
lymphoma.
Abstract: http://links.ealert.nature.com/ctt?kn=46&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=13&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Reviews Goes Clinical!
In April 2009, Nature Clinical Practice Rheumatology was completely
redesigned and became Nature Reviews Rheumatology, bringing all the qualities
of the top-ranked* life science review series to the clinical sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=73&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
*2007 Journal Citation Report (Thomson Reuters, 2008)
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=28&m=33524115&r=MTc2OTYyOTQ2MwS2&b=2&j=NTI2MzkxODcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
